AtriCure, Inc. (ATRC) FY2025 10-K Annual Report
AtriCure, Inc. (ATRC) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
AtriCure, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model centers on medical devices for cardiac surgery and related treatments
- • Enhanced emphasis on cybersecurity risk management aligning with NIST Cybersecurity Framework and Zero Trust principles this fiscal year
- • Integration of cybersecurity risk assessments into enterprise risk management with Board oversight introduced or strengthened
- • Annual reviews of third-party service providers’ SOC 1 and SOC 2 reports to manage supply chain cybersecurity risks
- • Noteworthy focus on potential material adverse effects of cybersecurity incidents on business and financial outcomes
Management Discussion & Analysis
- • Revenue $534.5M, up 14.9% YoY ($465.3M in 2024); growth driven by pain management (+32.5%), open ablation (+16.3%), appendage management (+17.5%), minimally invasive ablation declined (−31.2%)
- • Gross margin 75.0% vs 74.7%, up 29 basis points; operating margin loss improved to −1.8% vs −8.6%; net loss narrowed to $11.4M (−2.1%) vs $44.7M (−9.6%)
- • Best segment: Appendage management revenue $178.1M, +17.5% YoY; worst: Minimally invasive ablation $31.5M, down 31.2%
- • Operating cash flow increased by $45.1M; financing inflows include $6.25M sale-leaseback; cash $167.4M; debt $61.9M with $61.9M borrowing capacity; capex ongoing for facility expansion
- • Management expects continued product innovation, clinical trial progress (LeAAPS, BoxX-NoAF), monitors inflation risks, and maintains liquidity via credit facility and shelf registration
Risk Factors
- • No specific or timely regulatory or legal risks detailed beyond general cybersecurity oversight frameworks
- • No geopolitical or macroeconomic threats identified with concrete exposure details
- • Cybersecurity risk management reliant on a limited IT leadership team with combined 60 years experience, potential expert concentration risk
- • No competitive or market disruption risks mentioned involving named competitors or new technology
- • No financial or structural risks such as leverage, concentration, or key-person dependencies explicitly highlighted
AtriCure, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$535M
▲ +14.9% YoY
Net Income
-$11M
▲ +74.4% YoY
Gross Margin
75.0%
▲ +29bp YoY
Operating Margin
-1.8%
▲ +683bp YoY
Net Margin
-2.1%
▲ +746bp YoY
ROE
-2.3%
▲ +737bp YoY
Total Assets
$654M
▲ +7.4% YoY
EPS (Diluted)
$-0.24
▲ +74.7% YoY
Operating Cash Flow
$57M
▲ +369.8% YoY
Source: XBRL data from AtriCure, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on AtriCure, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.